Sutro Biopharma Inc. (STRO)
1.45
-0.14 (-8.81%)
At close: Mar 03, 2025, 3:59 PM
1.50
3.81%
After-hours: Mar 03, 2025, 04:06 PM EST
No 1D chart data available
| Bid | 1.42 |
| Market Cap | 119.15M |
| Revenue (ttm) | 161.77M |
| Net Income (ttm) | -124.58M |
| EPS (ttm) | -1.55 |
| PE Ratio (ttm) | -0.93 |
| Forward PE | -0.55 |
| Analyst | Buy |
| Ask | 1.68 |
| Volume | 1,285,946 |
| Avg. Volume (20D) | 1,053,184 |
| Open | 1.60 |
| Previous Close | 1.59 |
| Day's Range | 1.44 - 1.62 |
| 52-Week Range | 1.44 - 6.13 |
| Beta | 1.15 |
About STRO
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-H...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 27, 2018
Employees 306
Stock Exchange NASDAQ
Ticker Symbol STRO
Website https://www.sutrobio.com
Analyst Forecast
According to 7 analyst ratings, the average rating for STRO stock is "Buy." The 12-month stock price forecast is $12, which is an increase of 730.45% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Sutro Biopharma Inc. is scheduled to release its earnings on Mar 24, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
3 months ago
-12.88%
Sutro Biopharma shares are trading lower after the...
Unlock content with
Pro Subscription
5 months ago
-17.78%
Sutro Biopharma shares are trading lower. The company announced updated data from the ongoing Phase 1b study of luveltamab tazevibulin in combination with bevacizumab for patients with epithelial ovarian cancer in a poster presentation at the 2024 ESMO Congress.
